Mon, Jul 28, 2014, 4:13 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Horizon Pharma, Inc. (HZNP) Message Board

  • biotechad biotechad Dec 3, 2012 2:12 PM Flag

    PSDV (Mcap $29 M) 3x Approved Drugs // 1x in Phase 3 // US NDA filing in January = 10 BAGGER EASILY

     

    THIS LOW FLOAT ROCKET IS DEFINITELY THE CHEAPEST BIOTECH OUT THERE ..PLEASE DO YOUR OWN DD FOLKS..

    This undiscovered low float Stock will hit $7++ before FDA approval in 1H 2013 .PSDV will move into double digits easily with FDA approval for Blockbuster candidate Iluven for DME .There is NO FDA approved drugs for DME (Diabetic Macular Edema) a Blockbuster Market . Iluven is approved in Europe and Market launch will start during 2013

    Upon US approval of ILUVIEN, pSivida would be entitled to receive a $25 million milestone payment from Alimera and 20 percent of net profits, as defined, on sales of the drug by Alimera.

    DME is a potentially blinding disease that affects over one million people in the United States. Currently there are no FDA approved drugs for the treatment of DME.The U.S. market for DME is $1.5 billion to $4 billion.

    Psivida (PSDV)

    Market Cap: $29.5 M
    Cash: $17.65 M
    Price: $1.27

    Shares Out: 23.3

    Our proven proprietary technologies enable us to achieve highly focused, long-term delivery of therapeutics. We have developed three of the only four products approved by either the US or EU for the long-term, sustained-released delivery of drug to treat chronic eye disease.

    Our most recently approved product, ILUVIEN® for diabetic macular edema (DME), has received marketing authorization in the UK, Austria, France, Germany and Portugal, with approvals in Italy and Spain anticipated in the coming months. These marketing authorizations followed a positive outcome of the European Decentralized Procedure involving these seven countries. ILUVIEN, licensed to Alimera Sciences, Inc. (Alimera), is approved for use in the treatment of vision imparement associated with chronic DME considered insufficiently responsive to available therapies.

    ............................................

    This topic is deleted.
 
HZNP
9.15-4.75(-34.17%)4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.